Endocrine Abstracts

Introduction: Pancreatic neuroendocrine tumors (panNETs) are often inoperable at diagnosis. The mTORC1 inhibitor everolimus is approved for the treatment of advanced NETs. Unfortunately, the development of resistance against everolimus limits its clinical efficacy.Aim: Our aim was to establish an everolimus-resistant panNET cell line to find common mechanisms of resistance.Methods: Pancreatic neuroendocrine tumor cells (BON1) were ...

Cyclin-dependent kinases (CDKs) are crucial for the cell cycle regulation and alterations of the cell cycle and its regulators are often observed in human malignancies. CDK4/6 in particular orchestrates the G1 phase progression and the G1/S transition. Here we investigated the in vitro effects of the CDK4/6 inhibitor LEE001(Novartis, Basel) on the human neuroendocrine tumor (NET) cell lines BON1, QGP1 and NCI-H727. The cells were treated with different concentrations ...

Introduction: In our previous studies we found that the combination of 13-cis retinoic acid (13cRA) and lovastatin significantly reduced tumour growth in a mouse phaeochromocytoma allograft model, with the lowest microvessel density in the combination-treated tumours. We have now investigated the effect of 13cRA plus lovastatin on neuroendocrine (BON1, H727) and non-endocrine tumour (HepG2, Huh7) cell viability and signalling pathways (EGFR, AKT, ERK, p70S6K) to eluci...

The recreational use of cannabis is becoming more widespread since many countries, including parts of Europe, are currently discussing legalisation. Moreover, the medical use of cannabinoids is already established and has many indications such as multiple sclerosis-induced spasticity or supportive therapy in the case of tumour-associated pain or loss of weight or appetite. However, the effects of cannabinoids on tumour growth still remain largely unexplored in many tumour enti...